

*Abstract of the Disclosure*

The invention relates to pharmaceutical compositions for sparingly soluble therapeutic agents as well as to a process for the preparation of such compositions. The solubiliser is polyglycerol fatty acid ester or sorbitan fatty acid ester in combination with lipophilic excipients and nonionic surfactants.

of the present invention is a pharmaceutical composition comprising a sparingly soluble therapeutic agent, a polyglycerol fatty acid ester or a sorbitan fatty acid ester, a lipophilic excipient and a nonionic surfactant. The polyglycerol fatty acid ester or the sorbitan fatty acid ester is present in an amount of from 0.1 to 10% by weight, based on the total weight of the composition. The lipophilic excipient is present in an amount of from 0.1 to 10% by weight, based on the total weight of the composition. The nonionic surfactant is present in an amount of from 0.1 to 10% by weight, based on the total weight of the composition. The sparingly soluble therapeutic agent is present in an amount of from 0.1 to 10% by weight, based on the total weight of the composition. The composition is suitable for oral, parenteral, topical, or transdermal administration.